bpc-157 dosage humans Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or bpc-157 dosage human clinical data
Description
P.SerneelsJ.et al (2019)

Mato, J

Is this a ghk-cu reconstitution calculator

If they give you hesitancy with that, then thats a red flag

I am still not having a ton of pain in my arms and hands
BPC-157 increases VEGF expression explaining improved revascularization in injured tissues
